Establishment Labs Expects Q4 2025 Revenue of $64M to $65M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
The company said, "Establishment Labs' preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 million to $17.5 million from Motiva sales in the United States. Based on the expected range for fourth quarter revenue."
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is 82.88 USD with a low forecast of 75.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 69.180
Low
75.00
Averages
82.88
High
90.00
Current: 69.180
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanguard Health Care ETF Sees 14.9% Insider Buying in Holdings
- Insider Buying Ratio: The Vanguard Health Care ETF (VHT) shows that 14.9% of its holdings have experienced insider buying in the past six months, indicating strong confidence from executives that could positively influence investor sentiment.
- Teleflex Activity: Teleflex (TFX), comprising 0.07% of VHT, has seen 5 directors and officers purchase shares in the last six months, suggesting internal optimism about its stock price, which may bolster market confidence in the company.
- Establishment Labs Activity: Establishment Labs (ESTA), ranked 216th in VHT with a holding value of approximately $3,464,977, recently had 2 directors and officers file Form 4s indicating purchases, reflecting a positive outlook on the company's future growth.
- ETF Holding Value: The Vanguard Health Care ETF holds a total of $13,702,466 worth of TFX, making it the 106th largest holding, showcasing the ETF's strategic investment in the healthcare sector, which may attract more investors focused on this industry.
Continue Reading
Establishment Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Executive Presentation: Establishment Labs CEO Peter Caldini and CFO Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 AM PT, showcasing the company's latest advancements in women's health.
- Live Webcast: The presentation will be available via a live webcast on Establishment Labs' investor relations website, allowing global investors to gain real-time insights into the company's strategic direction and market dynamics, thereby enhancing investor confidence.
- Product Innovation: Establishment Labs has delivered over four million Motiva® devices since 2010, establishing the company as a leader in breast aesthetics and reconstruction, significantly improving patient satisfaction and safety standards.
- Technological Strength: With over 200 patent applications and more than 100 scientific studies, the company demonstrates its innovative capabilities and competitive edge in the women's health technology sector.
Continue Reading